Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norovirus GI.1/GII.4 Bivalent VLP Vaccine Assay Validation
NCT02475278Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of NoV GI.1/GII.4 bivalent VLP vaccine in norovirus infection, sponsored by Takeda. Started Feb 2015; status: completed.
02
Drugs
NoV GI.1/GII.4 bivalent VLP vaccine
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT02475278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475278.